Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.95), $0.12 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $11.48 million versus the consensus estimate of $20 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.